• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

UGT2B7 Gene Record

  • Summary
  • Interactions
  • Claims
  • UGT2B7 7364 Druggable Genome

    Alternate Names:

    7364
    UDP GLUCURONOSYLTRANSFERASE FAMILY 2 MEMBER B7
    UGT2B7
    UDPGT 2B7
    UDPGT 2B9
    UDPGT2B7
    UDPGTH2
    UDPGTh-2
    UGT2B9
    600068
    12554
    ENSG00000171234
    OTTHUMG00000129404
    PA361

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (0 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME

    Publications:

    Tian JN et al., 2012, UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients., Pharmacogenomics
    Crettol S et al., 2006, ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment., Clin Pharmacol Ther
    Baber M et al., 2015, The pharmacogenetics of codeine pain relief in the postpartum period., Pharmacogenomics J
    Milosheska D et al., 2016, Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters., Br J Clin Pharmacol
    Inoue K et al., 2016, Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy., Eur J Clin Pharmacol
    Zhou Y et al., 2015, Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients., Drug Metab Pharmacokinet
    Singkham N et al., 2013, Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients., Eur J Clin Pharmacol
    Li J et al., 2018, The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin., Support Care Cancer
    Sastre JA et al., 2015, Influence of uridine diphosphate-glucuronyltransferase 2B7 (UGT2B7) variants on postoperative buprenorphine analgesia., Pain Pract
    Ning M et al., 2019, Roles of UGT2B7 C802T gene polymorphism on the efficacy of morphine treatment on cancer pain among the Chinese han population., Niger J Clin Pract
    Nielsen LM et al., 2017, Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics., Eur J Pharm Sci
    Matic M et al., 2014, Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort., Pharmacogenomics
    Bastami S et al., 2014, Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption., Basic Clin Pharmacol Toxicol
    Darbari DS et al., 2008, UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease., Am J Hematol
    Coulbault L et al., 2006, Environmental and genetic factors associated with morphine response in the postoperative period., Clin Pharmacol Ther
    Holthe M et al., 2002, Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy., Eur J Clin Pharmacol
    House L et al., 2015, In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7., Xenobiotica
    Yang Z et al., 2020, Influences of UGT2B7 rs7439366 and rs12233719 Polymorphisms on Fentanyl Sensitivity in Chinese Gynecologic Patients., Med Sci Monit
    Shen C et al., 2017, Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy., Seizure
    Ma CL et al., 2015, SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy., Pharmacogenomics
    Cusato J et al., 2016, Efavirenz pharmacogenetics in a cohort of Italian patients., Int J Antimicrob Agents
    Haas DW et al., 2014, Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes., J Antimicrob Chemother
    Sarfo FS et al., 2014, Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients., J Antimicrob Chemother
    Cortes CP et al., 2013, Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor., Ther Drug Monit
    Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
    Kwara A et al., 2009, CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients., AIDS
    Bélanger AS et al., 2009, Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine., Drug Metab Dispos
    Varenhorst C et al., 2015, Effect of genetic variations on ticagrelor plasma levels and clinical outcomes., Eur Heart J
    Wang H et al., 2011, Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen., Biochem Pharmacol
    Ghodke Y et al., 2012, PharmGKB summary: zidovudine pathway., Pharmacogenet Genomics
    Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
    Thorn CF et al., 2011, PharmGKB summary: carbamazepine pathway., Pharmacogenet Genomics
  • APREPITANT   UGT2B7

    Interaction Score: 1.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26053558


    Sources:
    PharmGKB

  • EFAVIRENZ   UGT2B7

    Interaction Score: 1.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26774523 24729586 24080498 23172109 20860463 19779319 19487252


    Sources:
    PharmGKB

  • FLURBIPROFEN   UGT2B7

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21856293


    Sources:
    PharmGKB

  • TICAGRELOR   UGT2B7

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25935875


    Sources:
    PharmGKB

  • MORPHINE   UGT2B7

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31607718 28063968 25340733 24703092 17724700 16580900 12185559


    Sources:
    PharmGKB

  • CODEINE   UGT2B7

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25752520


    Sources:
    PharmGKB

  • OXYCODONE   UGT2B7

    Interaction Score: 0.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29502154


    Sources:
    PharmGKB

  • BUPRENORPHINE   UGT2B7

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24256307


    Sources:
    PharmGKB

  • LAMOTRIGINE   UGT2B7

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27096250 26790665 26213157 23263737


    Sources:
    PharmGKB

  • OXCARBAZEPINE   UGT2B7

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28837897 25823783


    Sources:
    PharmGKB

  • LOSARTAN   UGT2B7

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • METHADONE   UGT2B7

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22676193 17178267


    Sources:
    PharmGKB

  • FENTANYL   UGT2B7

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    32401749


    Sources:
    PharmGKB

  • ZIDOVUDINE   UGT2B7

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22960662


    Sources:
    PharmGKB

  • IBUPROFEN   UGT2B7

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • FLUVASTATIN   UGT2B7

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CARBAMAZEPINE   UGT2B7

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21738081


    Sources:
    PharmGKB

  • OXAZEPAM   UGT2B7

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOVASTATIN   UGT2B7

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMVASTATIN   UGT2B7

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATORVASTATIN   UGT2B7

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000171234

    • Version: 101_38

    Alternate Names:
    UGT2B7 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: UGT2B7

    • Version: 18-August-2020

    Alternate Names:
    PA361 PharmGKB ID

    Gene Info:

    Publications:
    Baber M et al., 2015, The pharmacogenetics of codeine pain relief in the postpartum period., Pharmacogenomics J
    Darbari DS et al., 2008, UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease., Am J Hematol
    Matic M et al., 2014, Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort., Pharmacogenomics

  • HingoraniCasas: ENSG00000171234

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000171234 Gene Symbol
    UGT2B7 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21